Athira Pharma (ATHA) shares surged more than 60% after it secured exclusive global rights to a Phase-III breast cancer drug and announced $236 million in financing. The package includes a $90 million private placement and potential warrant proceeds of $146 million. ATHA is set to open at its highest level in more than a year.